Inactive Instrument

Context Therapeutics Inc.

US21077P1084

Biotechnology & Medical Research

Context Therapeutics Inc. announced that it has received $99.992767 million in funding from Ally Bridge Group, Avidity Partners, LLC, Blue Owl Healthcare Opportunities, Deep Track Capital, LP, Driehaus Capital Management LLC, Great Point Partners, LLC

May 06, 2024

On May 6, 2024, Context Therapeutics Inc., closed the transaction. As a part of the transaction, the company expects placement offering expenses will be approximately $5,200,000.

Latest news about Context Therapeutics Inc.

Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Context Therapeutics Inc. announced that it has received $99.992767 million in funding from Ally Bridge Group, Avidity Partners, LLC, Blue Owl Healthcare Opportunities, Deep Track Capital, LP, Driehaus Capital Management LLC, Great Point Partners, LLC	06/05	CI
Context Therapeutics Announces FDA Clearance of IND Application for A Phase 1 Clinical Trial of CTIM-76	02/05	CI
Context Therapeutics Inc. announced that it expects to receive $99.992767 million in funding from Ally Bridge Group, Avidity Partners, LLC, Blue Owl Healthcare Opportunities, Deep Track Capital, LP, Driehaus Capital Management LLC, Great Point Partners, LLC	01/05	CI
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers	01/04	CI
Context Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Context Therapeutics Inc. Amends its Collaboration and Licensing Agreement with Integral Molecular, Inc	06/03	CI
Context Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Context Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Context Therapeutics Inc. Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer	06/23/06	CI
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers	09/23/09	CI
Context Therapeutics Inc. Enrolls the First Patient in the Elona Study	04/23/04	CI
Context TherapeuticsÂ® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer	08/22/08	CI
Context Therapeutics Inc. Announces Research Collaboration and Licensing Agreement with Integral Molecular	29/22/29	CI
Context Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
Certain Warrants of Context Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2022.	19/22/19	CI
Certain Stock Options of Context Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2022.	19/22/19	CI
Certain Common Stock of Context Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2022.	19/22/19	CI
Context Therapeutics Extends Runway into First Quarter 2024	27/22/27	CI
Context Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Context Therapeutics and the Menarini Group Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Ona-XR and Elacestrant Combination	02/22/02	CI
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	12/22/12	CI
Certain Warrants of Context Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2022.	17/22/17	CI
Certain Stock Options of Context Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2022.	17/22/17	CI

Chart Context Therapeutics Inc.

Duration

Period

More charts

Centrexion Therapeutics Corp is a late clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to address the unmet medical need for the treatment of chronic pain. Its product candidate pipeline includes CNTX-4957, CNTX-0290, CNTX-6970, CNTX-2022 and CNTX-6016. Its product candidates are designed to treat pain conditions of multiple etiologies associated with a wide variety of common disease states. CNTX-4975 is designed to target and disrupt the signaling of pain-sensing nerve fibers. CNTX-0290 product candidate is an investigational small molecule SSTR4 agonist. CNTX-6970 is a potent and selective investigational CCR2 antagonist. CNTX-6970 is a small molecule intended to be administered orally. CNTX-2022 is a proprietary, high concentration topical gel formulation of lidocaine.

Sector

Biotechnology & Medical Research

Calendar

13/06/2024 - Annual General Meeting

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+43.34%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research